Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BCG Vaccine in Healthy 6-65 Year Olds
NCT04563273Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bcg vaccine in Tuberculosis (TB) (4 arms), sponsored by Zhifei Biological. Primary endpoint: Incidence of adverse events after vaccination at 6 months. Started Oct 2020; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04563273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563273.